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Background.  —  Recent  studies  have  suggested  that  ticagrelor  90  mg  twice  daily  provides  stronger
platelet  inhibition  than  prasugrel  10  mg  once  daily  in  acute  coronary  syndrome  patients  under-




Objectives.  —  To  compare  the  effects  of  ticagrelor  90  mg  twice  daily  and  prasugrel  10  mg  once
daily on  platelet  reactivity  in  patients  with  ST-segment  elevation  myocardial  infarction  (STEMI),
using: the  VerifyNow® P2Y12 (VN-P2Y12)  assay,  expressed  in  P2Y12 reaction  units  (PRU);  mea-
surement  of  the  vasodilator-stimulated  phosphoprotein  platelet  reactivity  index  (VASP-PRI;  %);
and light  transmission  aggregometry  (LTA),  expressed  as  residual  platelet  aggregation  (RPA;  %).
Abbreviations: ADP, adenosine diphosphate; CI, conﬁdence interval; HPR, high on-treatment platelet reactivity; LPR, low on-treatment
latelet reactivity; LTA, light transmission aggregometry; MFI, median ﬂuorescence intensity; PCI, percutaneous coronary intervention; PFT,
latelet function test; PGE1, prostaglandin E1; PRI, platelet reactivity index; PRU, P2Y12 reaction units; RPA, residual platelet aggregation;
so-TRAP, iso-thrombin receptor activating peptide; STEMI, ST-segment elevation myocardial infarction; VN-P2Y12, VerifyNow® P2Y12; VASP,
asodilator-stimulated phosphoprotein.
∗ Corresponding author. Bureau 236, Institut de Cardiologie, Pitié-Salpêtrière University Hospital, 47-83, boulevard de l’Hôpital, 75013
aris, France.
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Methods.  —  Platelet  reactivity  was  evaluated  prospectively  using  the  three  assays  30  days  after
primary PCI  in  118  patients  with  STEMI  on  a  maintenance  dose  of  prasugrel  10  mg  once  daily
(n =  60)  or  ticagrelor  90  mg  twice  daily  (n  =  58).
Results.  —  On-treatment  platelet  reactivity,  assessed  by  the  VN-P2Y12 assay,  was  lower  for
ticagrelor  compared  with  prasugrel  (20.91  ±  4.59  PRU  vs.  43.50  ±  6.98  PRU;  P  =  0.008)  but
was not  signiﬁcantly  different  when  using  the  more  speciﬁc  VASP-PRI  assay  (13.05  ±  1.61%  vs.
17.44 ±  1.97%;  P  =  0.09)  or  RPA  assessed  by  LTA  (10.49  ±  1.44%  vs.  7.20  ±  1.27%;  P  =  0.09).
Conclusions.  —  The  difference  in  platelet  reactivity  between  ticagrelor  and  prasugrel  varies
according to  the  platelet  function  test  in  patients  with  STEMI.  The  differences  observed  may
be related  more  to  the  tests  than  to  the  drugs  used.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Contexte.  —  Des  études  récentes  ont  suggéré  que  le  ticagrelor  90  mg  en  deux  prises  par  jour
entraînait  une  inhibition  plaquettaire  plus  forte  que  le  prasugrel  10  mg  chez  les  patients  admis
pour SCA  et  traités  par  angioplastie.
Objectifs.  —  Comparer  l’effet  sur  la  réactivité  plaquettaire  du  ticagrelor  90  mg  en  deux  prises
par jour  et  du  prasugrel  10  mg  en  une  prise  par  jour  chez  des  patients  présentant  un  SCA  avec  sus-
décalage  du  segment  ST  en  utilisant  la  mesure  du  PRU  par  le  VerifyNow® (VN)-P2Y12,  la  mesure
de l’index  de  réactivité  plaquettaire  (IRP  ;  %)  par  la  phosphorylation  de  la  protéine  VASP  et  la
mesure de  l’agrégation  plaquettaire  résiduelle  (APR  ;  %)  par  l’agrégométrie  par  transmission
lumineuse  (LTA).
Méthodes.  —  La  réactivité  plaquettaire  a  été  évaluée  prospectivement  à  30  jours  de
l’angioplastie  primaire  chez  118  patients  ayant  présenté  un  SCA  avec  sus-décalage  du  segment
ST ;  60  sous  une  dose  d’entretien  de  prasugrel  et  58  sous  ticagrelor.
Résultats.  —  Le  niveau  de  réactivité  plaquettaire  évaluée  par  le  VN-P2Y12 était  plus  faible  sous
ticagrelor  en  comparaison  au  prasugrel  (20,91  ±  4,59  PRU  vs  43,50  ±  6,98  PRU  ;  p  =  0,008)  mais
pas signiﬁcativement  différent  avec  un  test  plus  spéciﬁque  comme  le  VASP  (13,05  ±  1,61  %
vs 17,44  ±  1,97  %  ;  p  =  0,09)  ou  plus  global  comme  l’APR  évaluée  par  LTA  (10,49  ±  1,44  %  vs
7,20 ±  1,27  %  ;  p  =  0,09).
Conclusions.  — La  mesure  de  la  réactivité  plaquettaire  par  le  VASP  et  la  LTA  sous  ticagrelor
en comparaison  au  prasugrel  diffèrent  des  données  du  VerifyNow®.  Les  différences  observées
pourraient  être  plus  liées  aux  tests  utilisés  qu’aux  molécules  elles-mêmes.












New  P2Y12 inhibitors  are  now  recommended  as  the  ﬁrst-
line  antiplatelet  therapies  in  patients  with  acute  coronary
syndrome  undergoing  percutaneous  coronary  intervention
(PCI);  both  prasugrel  and  ticagrelor  provide  greater  platelet
inhibition  than  clopidogrel  and  overcome  high  on-treatment
platelet  reactivity  (HRP),  leading  to  a  better  outcome  [1—3].
In  daily  clinical  practice,  the  choice  between  these  two
drugs  for  patients  with  ST-segment  elevation  myocardial
infarction  (STEMI)  undergoing  primary  PCI,  in  the  absence
of  a  head-to-head  comparison,  is  driven  by  contraindica-
tions  or  subgroup  analyses  of  pivotal  trials  [4—7].  In  addition,
pharmacodynamic  studies  also  support  the  decision-making
process  [8].  Prasugrel  and  ticagrelor  display  similar  phar-
macodynamic  proﬁles  after  loading  doses  in  patients  with
STEMI  [9].  However,  stronger  platelet  inhibition,  assessed
by  the  VerifyNow® P2Y12 assay  (VN-P2Y12;  Accumetrics,  San
Diego,  CA,  USA)  during  the  maintenance  phase,  has  been
P
9
peported  for  ticagrelor  90  mg  twice  daily  compared  with  pra-
ugrel  10  mg  once  daily  [8—10].  This  ﬁnding  was  also  found
n  one  study  when  using  the  vasodilator-stimulated  phospho-
rotein  platelet  reactivity  index  (VASP-PRI)  measurement,
n  assay  that  speciﬁcally  measures  the  drug  effect  [11].
The  aim  of  our  study  was  to  compare  the  antiplatelet
ffects  of  ticagrelor  90  mg  twice  daily  and  prasugrel  10  mg
nce  daily  in  post-STEMI  patients,  using  three  different
latelet  function  tests  (PFTs)  (VASP-PRI,  VN-P2Y12 and  light
ransmission  aggregometry  [LTA]).
ethods
opulationatients  with  STEMI  on  a  maintenance  dose  of  ticagrelor
0  mg  twice  daily  or  prasugrel  10  mg  once  daily  following





































































































t  the  physician’s  discretion.  One  month  after  discharge,
latelet  reactivity  was  evaluated  using  VASP-PRI,  VN-P2Y12
nd  LTA  assays  on  the  same  blood  sample.  Patients  with  a
ow  platelet  count  (<  150,000/mL)  were  excluded.  Patient
haracteristics  were  entered  into  a  prospective  web-based
egistry,  including  drug  intake  to  evaluate  potential  drug-
rug  interaction.  The  Pitié-Salpêtrière  University  Hospital
thics  Committee  approved  the  protocol  and  the  study  was
onducted  in  accordance  with  the  Declaration  of  Helsinki.
aboratory procedures
lood  was  collected  into  Becton-Dickinson  3.2%  citrate  vac-
ette  tubes  by  venous  puncture  after  discarding  the  ﬁrst
L  of  blood.  Pharmacodynamic  evaluation  was  performed
imultaneously  for  the  three  PFTs.
Phosphorylation  of  the  VASP  was  measured  with  a  Beck-
an  Coulter  FC500  cytometer  (Beckman  Coulter,  Villepinte,
rance)  according  to  the  manufacturer’s  instructions  and
revious  studies  [12].  Blood  samples  were  incubated  in  vitro
ith  adenosine  diphosphate  (ADP)  and  prostaglandin  E1
PGE1)  before  ﬁxation.  The  VASP-PRI  measured  by  a
ow  cytometer  was  calculated  from  the  median  ﬂuo-
escence  intensity  (MFI)  for  each  condition  according  to
he  formula:  VASP-PRI  =  ([MFI  (PGE1)  —  MFI  (PGE1 +  ADP)]/MFI
PGE1])  ×  100.
For  the  VN-P2Y12 assay,  samples  were  run  according  to
he  package  insert.  Results  were  expressed  in  P2Y12 reaction
nits  (PRU),  in  response  to  iso-thrombin  receptor  activat-
ng  peptide  (iso-TRAP)  and  ADP-PGE1,  and  as  percentage  of
nhibition,  corresponding  to  the  ratio  of  the  results  of  the
DP-PGE1 and  iso-TRAP  channels.
For  LTA,  platelet-rich  plasma  was  obtained  by  centrifuga-
ion  of  citrated  whole-blood  at  100  g  for  10  minutes  at  20 ◦C.
latelet-poor  plasma  was  obtained  by  further  centrifuga-
ion  at  2250  g  for  15  minutes.  In  vitro  platelet  aggregation
n  platelet-rich  plasma  was  measured  at  37 ◦C  by  LTA  (model
90-4D;  Chrono-Log  Corp.,  Kordia,  The  Netherlands)  and  was
nduced  by  the  addition  of  ADP  (Sigma-Aldrich,  Saint  Quentin
allavier,  France)  at  a  ﬁnal  concentration  of  20  mol/L.
ll  measurements  were  performed  in  duplicate  and  results
ere  expressed  in  terms  of  maximal  platelet  aggregation
MPA)  and  residual  platelet  aggregation  (RPA)  measured  at
 minutes.  Prespeciﬁed  criteria  used  to  deﬁne  non-evaluable
amples  were:  lack  of  sufﬁcient  signal,  haemolysis,  platelet
ount  <  150,000/mL  and  an  unstable  baseline.
tudy objective
he  primary  objective  of  the  study  was  to  compare  the  level
f  platelet  inhibition  30  days  after  the  acute  event  during
aintenance  therapy  with  ticagrelor  90  mg  twice  daily  or
rasugrel  10  mg  once  daily,  using  three  validated  PFTs.  The
econdary  objectives  were  to  compare  the  proportions  of
atients  with  high  on-treatment  platelet  reactivity  (HPR)
nd  low  on-treatment  platelet  reactivity  (LPR),  using  the
stablished  cut-offs  of  VASP-PRI  >  50%,  PRU  >  208  (VN-P2Y12)
nd  RPA  >  46.2%  (LTA)  for  HPR  and  VASP-PRI  <  16%,  PRU  <  85
VN-P2Y12)  and  RPA  <  10%  (LTA)  for  LPR  [13,14]. Based  on
revious  platelet  function  studies  [10],  55  patients  in  each
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rror  of  0.05,  assuming  a 20%  standard  deviation,  to  demon-
trate  that  one  of  the  two  drugs  is  superior  to  the  other.
tatistical analysis
ontinuous  variables  following  a  normal  distribution  are  pre-
ented  as  means  ±  standard  deviations  and  were  compared
sing  Student’s  t-test.  Categorical  variables  are  presented
s  counts  and  percentages  and  were  compared  using  Fisher’s
xact  test.  Results  are  reported  as  means  ±  standard  errors
f  the  mean  for  the  detailed  analyses.  All  P  values  are  two-
ided  and  a  value  of  P  <  0.05  was  considered  signiﬁcant.
he  relationship  between  the  three  assays  was  assessed  by
earson’s  correlation  coefﬁcient.  Normal  distribution  of  the
ariables  was  evaluated  for  continuous  variables  using  the
olmogorov-Smirnov  test.  All  analyses  were  performed  with
he  use  of  PRISM,  version  5  (GraphPad  Software,  Inc.,  LA
olla,  CA,  USA).  All  the  authors  had  full  access  to  and  take
ull  responsibility  for  the  integrity  of  the  data.
esults
tudy population
 total  of  118  patients  with  STEMI  exposed  to  a  10  mg  main-
enance  dose  of  prasugrel  once  daily  (n  =  60)  or  a  90  mg
aintenance  dose  of  ticagrelor  twice  daily  (n  =  58)  agreed
o  participate  in  the  study  and  were  assessed  for  platelet
unction  testing  at  the  1-month  follow-up  visit.  Baseline
haracteristics  are  presented  in  Table  1.
latelet reactivity
latelet  reactivity  evaluated  with  the  VN-P2Y12 assay  was
ower  with  ticagrelor  than  with  prasugrel  (20.91  ±  4.59
RU  vs.  43.50  ±  6.98  PRU;  P  =  0.008),  but  the  differ-
nces  were  not  statistically  different  when  using  VASP-
RI  (13.05  ±  1.61%  vs.  17.44  ±  1.97%;  P  =  0.09)  or  LTA
10.49  ±  1.44%  vs.  7.20  ±  1.27;  P =  0.09)  (Fig.  1,  Table  2).  The
PR  rates  for  prasugrel  and  ticagrelor  were  1.7%  vs.  0%  with
ASP-PRI,  0%  vs.  1.66%  with  VN-P2Y12 and  0%  vs.  0%  with
TA,  respectively.  The  LPR  rates  for  prasugrel  and  ticagrelor
ere  81.7  ±  5.0%  vs.  94.9  ±  5.0%  (P  =  0.03)  with  VN-P2Y12 and
7.3  ±  6.4%  vs.  51.0  ±  7.2%  (P  =  0.09)  with  LTA,  respectively
Fig.  2).
orrelation between tests
here  was  a modest  but  signiﬁcant  correlation  between
ASP-PRI  and  VN-P2Y12 (r  =  0.37,  95%  conﬁdence  interval
CI]:  0.19  to  0.52;  P  <  0.0001)  and  between  LTA  and  VN-P2Y12
r  =  0.30,  95%  CI:  0.11  to  0.46;  P  =  0.002),  but  there  was  no
orrelation  between  LTA  and  VASP-PRI  (r  =  —0.07,  95%  CI:
0.27  to  —0.12;  P  =  0.47)  (Fig.  3).
orrelation with published datao  our  knowledge,  in  the  literature,  the  PFT  that  has  been
sed  most  frequently  to  compare  ticagrelor  and  prasugrel  is
he  VN-P2Y12 assay  (Table  3),  and  our  ﬁndings  are  support-
ve  of  higher  platelet  inhibition  with  ticagrelor  than  with
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Table  1  Baseline  characteristics.
Characteristic  All  patients  (n  =  118)  Ticagrelor  group  (n  =  58)  Prasugrel  group  (n  =  60)  P
Age  (years)  58.86  ±  1.03  59.97  ±  1.54  57.78  ±  1.37  0.29
Men  (%)  83.05  ±  3.47  84.48  ±  4.80  81.67  ±  5.04  0.69
Weight  (kg)  76.69  ±  1.34  75.64  ±  1.95  77.74  ±  1.84  0.43
BMI  26.24  ±  0.38  25.98  ±  0.50  26.50  ±  0.57  0.49
Low  weight  <  60  kg  (%)  12.71  ±  3.08  18.97  ±  5.19  6.67  ±  3.28  0.05a
BMI  >  30  (%) 16.10  ±  3.40 10.34  ±  4.03 21.67  ±  5.36  0.10
Diabetes  (%) 16.95  ±  3.47 15.52  ±  4.80 18.33  ±  5.04 0.69
Dyslipidaemia  (%) 38.98  ±  4.51 44.83  ±  6.59 33.33  ±  6.14 0.20
Smoker  (%)  72.03  ±  4.15  74.14  ±  5.80  70.00  ±  5.97  0.62
High  blood  pressure  (%)  36.44  ±  4.45  39.66  ±  6.48  33.33  ±  6.14  0.48
Family  history  of  CAD  (%)  27.12  ±  4.11  31.03  ±  6.13  23.33  ±  5.51  0.35
One-vessel  disease  (%)  62.71  ±  4.47  68.97  ±  6.13  56.67  ±  6.45  0.17
Two-vessel  disease  (%)  22.88  ±  3.88  17.24  ±  5.00  28.33  ±  5.87  0.15
Three-vessel  disease  (%)  15.25  ±  3.32  15.52  ±  4.78  15.00  ±  4.65  0.93
Creatinine  clearance  (mL/min)  97.65  ±  3.10  88.69  ±  3.96  106.6  ±  4.51  0.003a
Ejection  fraction  (%)  51.29  ±  9.16  49.13  ±  1.41  53.34  ±  1.13  0.02a
Aspirin  (mg)  100  ±  0  100  ±  0  100  ±  0  1.00
Beta-blockers  (%)  91.53  ±  2.57  91.38  ±  3.72  91.67  ±  3.60  0.95
ACE  inhibitors  (%)  92.37  ±  2.45  91.38  ±  3.72  93.33  ±  3.25  0.69
Calcium  antagonists  (%)  8.47  ±  2.57  5.17  ±  2.93  11.67  ±  4.18  0.21
Statins  (%)  99.15  ±  0.84  98.28  ±  1.72  100  ±  0  0.99
Proton  pump  inhibitors  (%)  83.90  ±  3.398  79.31  ±  5.36  88.33  ±  4.18  0.18
Data are expressed as mean ± standard error of the mean. ACE: angiotensin-converting enzyme; BMI: body mass index; CAD: coronary
artery disease.
a Signiﬁcant difference.
Figure 1. Platelet reactivity at 1-month, according to different platelet function tests. LTA: light transmission aggregometry; VASP:
vasodilator-stimulated phosphoprotein; VN: VerifyNow®.
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Table  2  Results  of  the  three  different  platelet  function  tests  (VerifyNow® P2Y12, light  transmission  aggregometry  and
vasodilator-stimulated-phosphoprotein)  for  maintenance  doses  of  prasugrel  10  mg  once  daily  compared  with  ticagrelor
90  mg  twice  daily.
Prasugrel  10  mg  once  daily  Ticagrelor  90  mg  twice  daily  P
VN-P2Y12
No.  of  patients  (%)  60  (100)  58  (100)
Base  (iso-TRAP)  (PRU)  264.90  ±  5.76  259.70  ±  6.01  0.53
Patient  (ADP-PGE1)  (PRU)  43.50  ±  6.98  20.91  ±  4.59  0.008a
%  inhibition  84.30  ±  2.40  92.78  ±  1.36  0.003a
LTA
No.  of  patients  (%) 55  (91)  50  (86)
MPA  ADP  20  M  (%) 27.78  ±  1.45 25.80  ±  1.53 0.35
RPA  ADP  20  M  (%)  7.20  ±  1.27  10.49  ±  1.44  0.09
VASP
No.  of  patients  (%)  48  (80)  54  (93)
PRI  (%)  17.44  ±  1.97  13.05  ±  1.61  0.09
Data are expressed as mean ± standard error of the mean. ADP: adenosine diphosphate; iso-TRAP: iso-thrombin receptor activating
peptide; LTA: light transmission aggregometry; MPA: maximum platelet aggregation; PGE1: prostaglandin E1; PRI: platelet reactivity




















drasugrel  (Fig.  4).  However,  these  results  were  not  con-
rmed  with  the  VASP-PRI  assay,  a  more  speciﬁc  PFT,  or  with
TA,  a  global  PFT  evaluating  the  reactivity  of  platelet  P2Y12
eceptors  to  activation  by  ADP.
iscussionFTs  have  been  used  consistently  in  phase  2  studies  to  iden-
ify  the  appropriate  doses  of  ticagrelor  and  prasugrel  to
e  used  in  pivotal  trials;  they  have  been  also  used  after
igure 2. Rates of low on-treatment platelet reactivity (LPR)
ith ticagrelor or prasugrel, according to platelet function test.


























mivotal  trials  as  surrogate  endpoints  to  compare  these  drugs
ead-to-head  in  studies  with  small  sample  sizes.
Our  study  compared  these  drugs  using  a  multiple  PFT
pproach  in  a  real-life  STEMI  population,  and  the  main  ﬁnd-
ngs  are  as  follows:  there  are  discrepancies  between  PFTs
hen  comparing  the  antiplatelet  effects  of  maintenance
oses  of  ticagrelor  and  prasugrel;  LPR  is  a  common  ﬁnd-
ng,  with  variations  between  the  two  drugs  according  to  the
FT,  using  established  cut-offs;  PFTs  correlate  poorly  with
he  new  P2Y12 inhibitors.
Our  study  conﬁrms  previously  published  data  comparing
he  pharmacodynamics  of  the  two  drugs,  but  extends  the
nalysis  to  other  PFTs,  with  somewhat  different  ﬁndings.
ne  explanation  could  be  that  the  VN-P2Y12 assay  overesti-
ates  the  antiplatelet  effect  of  ticagrelor  as  a  consequence
f  the  adenosine  effects  of  ticagrelor,  ampliﬁed  by  the  addi-
ion  of  PGE1 during  the  testing  process.  Both  adenosine
nd  PGE1 increase  cyclic  adenosine  monophosphate  and,
ubsequently,  the  inhibitory  effect  measured  by  the  whole-
lood  bedside  VN-P2Y12 assay.  In  contrast,  LTA,  which  is  not
ffected  by  any  PGE1 additional  effect,  appears  to  be  less
ensitive  to  this  adenosine  effect.  In  fact,  these  tests  mea-
ure  the  same  phenomenon,  testing  the  same  pathway,  but
t  different  levels,  which  explains  the  difference  between
he  tests,  and  their  poor  correlation  and  poor  positive  pre-
ictive  value.
LPR  is  a common  ﬁnding  with  new  P2Y12 inhibitors,  and
he  rates  that  we  report  here  are  very  high,  using  the  recom-
ended  cut-off  values  for  deﬁning  LPR  [14]. These  ﬁndings
aise  the  question  of  the  need  for  a  tailored  antiplatelet
herapy,  given  the  established  association  between  LPR  and
leeding  complications  [15,16].
The  poor  correlation  found  between  the  three  tests
choes  the  results  found  previously  with  clopidogrel,  and












Table  3 Systematic  review  of  published  studies  comparing  ticagrelor  and  prasugrel  at  maintenance  dose.
Study  No.  of  patients:  total
(ticagrelor/prasugrel)
No. of  STEMI  patients:
total
(ticagrelor/prasugrel)
Study  design Study
population
Test Delay  Loading
Dose  to  test
Is there  a
difference?
Alexopoulos
et  al.,  2012
[10]




VN-P2Y12 Day  30 Yes
Alexopoulos
et  al.,  2012  [9]
55  (28/27) 55  (28/27) RCT  STEMI  VN-P2Y12 Hour  1—Day  5 No
Deharo  et  al.,
2013  [11]
96  (48/48)  Not  available  RCT  ACS  VASP;  LTA  Day  30  Yes
Alexopoulos
et  al.,  2013  [8]
30  (15/15) 7  (3/4)  RCT/crossover  Diabetics  with
ACS
VN-P2Y12 Day  30  Yes
ACS: acute coronary syndrome; LTA: light transmission aggregometry; RCT: randomized controlled trial; STEMI: ST-segment elevation myocardial infarction; VASP: vasodilator-stimulated
phosphoprotein; VN-P2Y12: VerifyNow® P2Y12.
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Figure 4. A. Overall mean P2Y12 reaction units (PRU) for tica-
grelor versus prasugrel at maintenance dose, compared with our
data and the mean PRU obtained in the four other studies. B. Overall
mean platelet reactivity index (PRI; %) for the two drugs at main-
tenance dose, compared with our data and the mean PRI obtained















an residual platelet aggregation (RPA) using adenosine diphosphate
0 mol/L (our study only). LTA: light transmission aggregometry;
ASP: vasodilator-stimulated phosphoprotein.
o  evaluating  platelet  reactivity,  using  a  combination  of  at
east  two  tests  to  deﬁne  the  response,  rather  than  relying  on
ne  test  only.  This  strategy  of  multiple  testing,  although  not
ractical,  appears  more  accurate  for  predicting  outcomes,
s  has  been  shown  recently  [17].  Another  strategy  would  be
o  repeat  the  PFTs  during  the  acute  and  maintenance  phases,
s  has  already  been  suggested  for  aspirin  [18]. However,  if
e  had  to  choose  just  one  test,  LTA,  in  our  opinion,  still
igure 3. Correlation and linear regression between the platelet
unction tests. LTA: light transmission aggregometry; PRI: platelet
eactivity index; PRU: P2Y12 reaction units; RPA: residual platelet









[Platelet  effect  of  prasugrel  and  ticagrelor  in  STEMI  
remains  the  gold  standard  for  evaluating  the  global  platelet
effect  of  the  new  P2Y12 inhibitors.
Study limitations
This  work  has  limitations.  First  of  all,  treatment  allocation
was  not  random  and  remained  at  the  clinician’s  choice,
driven  by  preferred  indication  or  contraindication,  which
could  inﬂuence  the  biological  difference  between  the  two
drugs.  Furthermore,  platelet  reactivity  was  evaluated  at  1-
month,  when  the  platelet  effect  of  the  drugs  is  more  stable
and  more  potent.  The  measure  does  not  reﬂect  the  level
of  platelet  inhibition  during  the  ﬁrst  day,  and  the  possible
difference  between  the  two  drugs,  which  may  have  clini-
cal  implications  for  early  ischaemic  events  or  haemorrhagic
complications.  Finally,  the  study  has  bias  inherent  to  a  bio-
logical  evaluation  of  drug  response  in  a  registry,  and  needs
repetition  and  conﬁrmation.  Other  tests  could  have  been
studied,  but  we  selected  three  different  testing  strategies.
Conclusions
In  conclusion,  the  new  P2Y12 inhibitors  provide  strong
platelet  inhibition  and  expose  many  patients  to  hyper-
response.  VASP  and  LTA  measurements  do  not  conﬁrm  the
superior  platelet  inhibition  of  ticagrelor  over  prasugrel  seen
with  VN-P2Y12.  Correlation  between  the  PFTs  is  poor,  sug-
gesting  that  comparison  between  these  two  drugs  based  on
a  single  test  is  spurious.
Disclosure of interest
M.K.  Research  grants  from  the  Fédération  Franc¸aise  de  Car-
diologie  and  Société  Francaise  de  Cardiologie.  J.S.  Research
grants  from  the  companies  Sanoﬁ-Aventis,  Daiichi-Sankyo
and  Eli  Lilly,  INSERM,  the  Fédération  Franc¸aise  de  Cardiolo-
gie  and  the  Société  Franc¸aise  de  Cardiologie;  consulting  fees
from  the  companies  Daiichi-Sankyo  and  Eli  Lilly;  and  lecture
fees  from  the  companies  AstraZeneca,  Daiichi-Sankyo  and
Eli  Lilly.
J.-P.C.  Research  grants  from  the  companies  Bristol-Myers
Squibb,  Sanoﬁ-Aventis,  Eli  Lilly,  Guerbet  Medical,  Medtronic,
Boston  Scientiﬁc,  Cordis,  Stago  and  Centocor,  the  Fon-
dation  de  France,  INSERM,  the  Fédération  Franc¸aise  de
Cardiologie  and  the  Société  Franc¸aise  de  Cardiologie;  con-
sulting  fees  from  the  companies  Sanoﬁ-Aventis,  Eli  Lilly  and
Bristol-Myers  Squibb;  and  lecture  fees  from  the  companies
Bristol-Myers  Squibb,  Sanoﬁ-Aventis  and  Eli  Lilly.
G.M.  Consulting  fees  from  the  companies  Bayer,
Boehringer  Ingelheim,  Gerson  Lehrman  Group,  Iroko  Cardio
International,  Lead-Up,  Luminex,  McKinsey  &  Co.,  Remed-
ica,  Servier,  WebMD,  Wolters  Kluwer  Health,  Bristol-Myers
Squibb,  AstraZeneca,  Biotronik,  Eli  Lilly,  The  Medicines
Company,  Menarini  Group,  Roche,  Sanoﬁ-Aventis,  Pﬁzer,
Daiichi-Sankyo  and  Medtronic,  the  Cardiovascular  Research
Foundation,  the  Europa  Organisation  and  the  TIMI  Study
Group;  and  grant  support  from  the  companies  Bristol-Myers
Squibb,  AstraZeneca,  Biotronik,  Eli  Lilly,  The  Medicines
Company,  Menarini  Group,  Sanoﬁ-Aventis,  Pﬁzer,  Roche,
[509
ccumetrics,  Medtronic,  Abbott  Laboratories,  Daiichi-
ankyo,  Nanosphere  and  Stentys.
The  other  authors  declare  that  they  have  no  conﬂicts  of
nterest  concerning  this  article.
Sources  of  funding:  This  study  was  supported  by  the
CTION  (Allies  in  Cardiovascular  Trials  Initiatives  and  Orga-
ized  Networks)  Group  (www.action-coeur.org).
eferences
[1] Task Force on the management of ST-segment elevation acute
myocardial infarction of the European Society of CardiologyS-
teg PG, James SK, et al. ESC Guidelines for the management
of acute myocardial infarction in patients presenting with ST-
segment elevation. Eur Heart J 2012;33:2569—619.
[2] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clo-
pidogrel in patients with acute coronary syndromes. N Engl J
Med 2009;361:1045—57.
[3] Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl
J Med 2007;357:2001—15.
[4] James S, Budaj A, Aylward P, et al. Ticagrelor versus clopido-
grel in acute coronary syndromes in relation to renal function:
results from the Platelet Inhibition and Patient Outcomes
(PLATO) trial. Circulation 2010;122:1056—67.
[5] Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel com-
pared with clopidogrel in patients undergoing percutaneous
coronary intervention for ST-elevation myocardial infarction
(TRITON-TIMI 38): double-blind, randomised controlled trial.
Lancet 2009;373:723—31.
[6] Steg PG, James S, Harrington RA, et al. Ticagrelor versus
clopidogrel in patients with ST-elevation acute coronary syn-
dromes intended for reperfusion with primary percutaneous
coronary intervention: a Platelet Inhibition and Patient Out-
comes (PLATO) trial subgroup analysis. Circulation 2010;122:
2131—41.
[7] Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical
beneﬁt of more intensive oral antiplatelet therapy with pra-
sugrel in patients with diabetes mellitus in the trial to assess
improvement in therapeutic outcomes by optimizing platelet
inhibition with prasugrel-thrombolysis in myocardial infarction
38. Circulation 2008;118:1626—36.
[8] Alexopoulos D, Xanthopoulou I, Mavronasiou E, et al.
Randomized assessment of ticagrelor versus prasugrel
antiplatelet effects in patients with diabetes. Diabetes Care
2013;36:2211—6.
[9] Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized
assessment of ticagrelor versus prasugrel antiplatelet effects
in patients with ST-segment-elevation myocardial infarction.
Circ Cardiovasc Interv 2012;5:797—804.
10] Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor ver-
sus prasugrel in acute coronary syndrome patients with high
on-clopidogrel platelet reactivity following percutaneous coro-
nary intervention: a pharmacodynamic study. J Am Coll Cardiol
2012;60:193—9.
11] Deharo P, Bassez C, Bonnet G, et al. Prasugrel versus ticagrelor
in acute coronary syndrome: a randomized comparison. Int J
Cardiol 2013;170:e21—2.
12] Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine
platelet reactivity in elderly coronary patients: the SENIOR-
PLATELET study. Eur Heart J 2012;33:1241—9.13] Bonello L, Tantry US, Marcucci R, et al. Consensus and
future directions on the deﬁnition of high on-treatment






population. Circulation 2012;126:A18797.10  
14] Tantry US, Bonello L, Aradi D, et al. Consensus and update on
the deﬁnition of on-treatment platelet reactivity to adenosine
diphosphate associated with ischemia and bleeding. J Am Coll
Cardiol 2013;62:2261—73.
15] Cayla G, Cuisset T, Silvain J, et al. Prasugrel monitoring
and bleeding in real world patients. Am J Cardiol 2013;111:
38—44.
16] Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition
of platelet aggregation after clopidogrel with post discharge
[M.  Kerneis  et  al.
bleeding events: assessment by different bleeding classiﬁca-
tions. Eur Heart J 2010;31:227—35.
17] O’Connor SA, Kerneis M, Martin R, et al. Clinical impact of high
on-prasugrel platelet reactivity in an acute coronary syndrome18] Patrono C, Rocca B. Aspirin: promise and resistance in the
new millennium. Arterioscler Thromb Vasc Biol 2008;28:
s25—32.
